Skip to content
Search

Latest Stories

CPAF 2023/24 screening questionnaire to be available from 3rd July for pharmacy contractors

pharmacy.biz Staff
By pharmacy.biz StaffJun 12, 2023
pharmacy.biz Staff
See Full Bio

The Community Pharmacy England has asked its members to complete the 2023/24 Community Pharmacy Assurance Framework (CPAF) screening questionnaire which will be available from Monday (3 July) until midnight on Sunday (30 July).

“As a result of NHS regulations introduced at the end of 2020, completion of CPAF is now a requirement of the Terms of Service. Therefore, contractors must complete the screening questionnaire and, if required, the full CPAF questionnaire,” said Community Pharmacy England. 

The short screening questionnaire consists of 10 questions. Contractors who use the NHS Business Services Authority (NHSBSA) Manage Your Service (MYS) portal will be required to complete the questionnaire on the portal. Contractors who are not yet signed up to MYS will be able to complete the questionnaire online.

The questions will be published on the NHSBSA website ahead of the 3rd July 2023 go-live date to give contractors advance notice of these.

Once the screening questionnaires have been completed, NHS England will then select a small number of pharmacies for a monitoring visit and/or to complete the full CPAF questionnaire.

Community Pharmacy England has published a short Briefing on the screening process.

“community pharmacy england”pharmacy contractorscpaf screening questionnaire

Related News

NHS to roll out RSV vaccinations across 200 pharmacies in 2025/26
News

RSV vaccination pilot to expand to 200 pharmacies in 2025/26

RPS backs Pharmacist Support "Gift in Wills" initiative
News

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

Pharmacy Business Conference is a must-attend for contractors — Here’s why

What I took away from the Pharmacy Business Conference 2025

Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA
Features

UK risks losing millions in NHS savings without stronger support for generics - BGMA

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc